Anteris Technologies Sees 51,701 Net CDI Decrease in June 2026 as Investors Shift Holdings to Nasdaq Shares

Anteris Technologies’ June 2026 CDI Total Falls to 15,193,455 Following Transfer to Nasdaq Shares

According to the Appendix 4A filing submitted on 3 July 2026, Anteris Technologies’ ASX-listed CDIs totaled 15,193,455 at June’s close, representing a decline of 51,701 from 15,245,156 at May’s end. Each CDI, trading under the ASX code AVR, corresponds on a one-to-one basis with the company’s underlying common stock, meaning each CDI equates to one share of the US-incorporated entity’s stock.

The decrease was entirely due to net transfers of securities from ASX CDIs to Nasdaq common stock, with no new issuances or cancellations beyond these cross-exchange movements. This ongoing migration is a structural element for investors observing the company’s ASX liquidity.

Details on the Movement of 51,701 Securities From ASX CDIs to Nasdaq Common Stock

For a dual-listed company like Anteris Technologies, investors holding AVR CDIs on the ASX can opt to convert their holdings into Nasdaq-listed common stock, shifting their economic exposure to the US market. The June 2026 Appendix 4A confirms this was the sole cause of the CDI decrease, with the 51,701 CDI reduction on the ASX exactly matching the increase in Nasdaq common stock.

This parity confirms the movement was a straightforward transfer rather than a new share issuance or buyback. When combined, the total shares across both exchanges remain consistent, though investors should consider outstanding options, warrants, and restricted stock units for a full view of dilution potential.

Nasdaq Common Stock Increases to 82,217,451 Shares by June End

As of 30 June 2026, Anteris Technologies held 82,217,451 common shares on Nasdaq, up from 82,165,750 at the end of May. This net increase of 51,701 aligns precisely with the CDI reduction on the ASX. The Nasdaq shares trade under the code AVRAAM.

The Nasdaq-listed shares significantly outnumber the ASX CDIs, indicating that most equity holders are now oriented toward the US exchange. The filing does not specify whether this shift is driven by increased US institutional participation or Australian investors’ preference for Nasdaq listings.

Restricted Stock Units Remain Stable at 1,861,816 in June

The company’s Restricted Stock Units (RSUs), identified by the ASX code AVRAAL, held steady at 1,861,816 during June 2026. No new grants, vestings, or forfeitures occurred during the month. RSUs serve as equity compensation for employees and executives and convert into common stock upon vesting under specified conditions.

The unchanged RSU count provides no new insight into equity compensation activity. While 1,861,816 RSUs remain outstanding, the filing does not detail vesting schedules or conversion timelines.

Options Pool Unchanged at 2,576,810 With Various Expiry Dates and Exercise Prices

Anteris Technologies’ options, trading under ASX code AVRAC, also showed no change during June 2026. The total outstanding options remained at 2,576,810, with no exercises, expirations, or new issuances recorded.

Options may dilute existing shareholders if exercised, depending on exercise prices relative to market values. The filing does not disclose specific exercise prices or expiry details; investors seeking further information should consult prior disclosures or the company’s latest annual report.

Warrants Steady at 5,385,000 With No Activity in June

The warrants, under ASX code AVRAA, remained constant at 5,385,000 as of June 2026, with no exercises, expirations, or new issuances during the month. Warrants, like options, can convert into equity and represent potential dilution.

This warrants total forms a significant part of Anteris Technologies’ fully diluted capital structure. Combined with RSUs and options, the total potential dilutive securities amount to approximately 9,823,626 instruments based on this filing. The company did not provide details on warrant exercise terms or expiry dates.

Summary of Anteris Technologies’ Capital Structure Across ASX and Nasdaq as of June 2026

At June 30, 2026, the company’s capital structure included 15,193,455 ASX-listed CDIs, 82,217,451 Nasdaq-listed common shares, 1,861,816 RSUs, 2,576,810 options, and 5,385,000 warrants. The combined issued equity and CDIs total approximately 97,410,906 securities before considering conversion of equity instruments.

The fully diluted total would be higher once RSUs, options, and warrants are converted, though actual dilution depends on instrument-specific conditions. Investors should factor this capital structure into their analysis of per-share metrics and potential dilution risks. This monthly securities statement did not include earnings, revenue, or operational guidance.

Implications of the CDI-to-Nasdaq Transfer Trend for ASX Liquidity

The net monthly reduction of 51,701 CDIs, while modest relative to the total CDI pool, is part of a broader trend often seen in dual-listed companies. Persistent transfers from one exchange to another can gradually impact liquidity and trading volumes on the exchange experiencing outflows. Continued transfers at this pace could cause the ASX CDI pool to shrink relative to the Nasdaq common stock pool.

This filing does not indicate whether the trend will persist, accelerate, or reverse. Investors should monitor future Appendix 4A filings to determine if the CDI-to-Nasdaq transfer pattern stabilizes or intensifies. The immediate share price impact from this routine disclosure was not evident from available data.

Regulatory Background: Anteris Technologies’ Monthly CDI Filings With ASX

As a foreign-incorporated company listed on the ASX via CHESS Depositary Interests, Anteris Technologies must file monthly Appendix 4A statements detailing CDIs on issue and changes to its securities structure, per ASX Listing Rules. These filings are routine regulatory requirements and do not imply material corporate events or strategic shifts.

The CDI structure allows Australian investors to hold economic interests in foreign-incorporated companies without direct ownership of foreign shares. The 1:1 ratio between AVR CDIs and underlying common stock means no embedded premium or discount exists in the CDI structure, though market prices may vary due to currency fluctuations, supply and demand, and trading session differences.

What to Watch in Upcoming Anteris Technologies Monthly Reports

The next Appendix 4A filing for July 2026 will reveal whether the CDI-to-Nasdaq transfer trend continued, stabilized, or reversed. Beyond these routine disclosures, investors will be attentive to operational updates related to Anteris Technologies’ core medical technology business, including its DurAVR transcatheter heart valve program, which remains the company’s primary clinical and commercial focus.

Any future changes in the options or warrants pools—through exercises, expirations, or new issuances—will be important to monitor due to their dilution potential. Likewise, RSU vesting events would reduce the AVRAAL count and increase common stock. Investors should evaluate these capital structure changes alongside operational or financial updates released separately, as they are not part of this monthly securities filing.